Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

A LoGiCal® Success at Analytical Services International

Published: Friday, April 20, 2012
Last Updated: Friday, April 20, 2012
Bookmark and Share
New product range from LGC Standards for therapeutic drug monitoring services.

Analytical Services International (ASI) at St George’s, University of London, UK, has been evaluating LoGiCal certified reference materials - a new product range from LGC Standards - for its therapeutic drug monitoring (TDM) services, where high quality reference standards are an essential requirement.

The use of high quality reference materials is equally important for the Company’s international proficiency testing scheme for immunosuppressive drugs, co-ordinated by Professor David Holt.

ASI recently validated the use of LoGiCal solutions of the immunosuppressant mycophenolic acid (MPA) and antiarrhythmic amiodarone metabolite desethylamiodarone (DEA) in its assays.

Michelle Moreton-Clack, TDM Service Manager, explained: “As part of our therapeutic drug monitoring service, we run assays for the measurement of MPA and DEA. We usually buy the drugs in powder form and weigh them out to prepare stock solutions for our assays. The LoGiCal range includes ISO Guide 34 certified solutions of MPA and DEA, which are really easy to use and save a lot of time by eliminating weighing stages. We validated both compounds against our existing stock solutions, and they showed good correlation; I am very pleased with the results.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

LGC Standards Partners with PRIMACYT to Improve Access to Hepatocytes for Drug Discovery Research
The partnership will facilitate a wider distribution of hepatocyte cells and allow greater access to these important in-vitro models.
Sunday, February 20, 2011
New Reference Materials Sourced to Meet the Needs of the World's Leading Toxicologists
Testing for ‘designer drugs’, ‘legal highs’ and other novel materials is a continuing challenge for clinical, forensic, sports testing and toxicology laboratories.
Tuesday, October 07, 2008
Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!